Cytoprotection by melatonin: The metabolic syndrome as an example

Autores
Cardinali, Daniel Pedro; Vigo, Daniel Eduardo
Año de publicación
2021
Idioma
español castellano
Tipo de recurso
parte de libro
Estado
versión publicada
Descripción
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Abstract: As for metabolic syndrome (MS), several risk factors for cardiovascular disease are known, including elevated blood pressure, hyperinsulinemia, glucose intolerance, and dyslipidemia. We hereby discussed the special role that the chronobiotic/cytoprotective properties of melatonin may have in prevention and treatment of MS. Melatonin levels are consistently reduced in MS. The therapeutic potential of melatonin includes improvement of sleep efficiency and antioxidant and anti-inflammatory properties that derive partly from its role as a metabolic regulator and mitochondrial protector. This article analyzes the actions of melatonin that are relevant to the attenuation of inflammatory responses in MS and how melatonin is effective to curtail MS in animal models of hyperadiposity and ischemic and nonischemic heart failure. The clinical data supporting the therapeutical use of melatonin in human MS are also reviewed. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e., in the 40–100 mg/day range). The off-label use of melatonin is finally discussed.
Fuente
Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021
Materia
MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
Nivel de accesibilidad
acceso embargado
Condiciones de uso
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/15402
Acceder
id RIUCA_402bb936d5f9e3da6afac05219fc3607
oai_identifier_str oai:ucacris:123456789/15402
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Cytoprotection by melatonin: The metabolic syndrome as an exampleCardinali, Daniel PedroVigo, Daniel EduardoMELATONINASINDROME METABOLICOINFLAMACIONDIABETESENVEJECIMIENTOINSULINAFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; ArgentinaFil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; ArgentinaAbstract: As for metabolic syndrome (MS), several risk factors for cardiovascular disease are known, including elevated blood pressure, hyperinsulinemia, glucose intolerance, and dyslipidemia. We hereby discussed the special role that the chronobiotic/cytoprotective properties of melatonin may have in prevention and treatment of MS. Melatonin levels are consistently reduced in MS. The therapeutic potential of melatonin includes improvement of sleep efficiency and antioxidant and anti-inflammatory properties that derive partly from its role as a metabolic regulator and mitochondrial protector. This article analyzes the actions of melatonin that are relevant to the attenuation of inflammatory responses in MS and how melatonin is effective to curtail MS in animal models of hyperadiposity and ischemic and nonischemic heart failure. The clinical data supporting the therapeutical use of melatonin in human MS are also reviewed. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e., in the 40–100 mg/day range). The off-label use of melatonin is finally discussed.Springerinfo:eu-repo/date/embargoEnd/2100-01-012021info:eu-repo/semantics/bookPartinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_3248info:ar-repo/semantics/parteDeLibroapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/15402978-3-030-61721-9 (online)10.1007/978-3-030-61721-9_22Cardinali, D.P., Vigo, D.E. Cytoprotection by Melatonin: The Metabolic Syndrome as an Example [en línea]. En: Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021 doi:10.1007/978-3-030-61721-9_22 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/15402Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaspainfo:eu-repo/semantics/embargoedAccess2025-07-03T10:58:57Zoai:ucacris:123456789/15402instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:58:57.869Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Cytoprotection by melatonin: The metabolic syndrome as an example
title Cytoprotection by melatonin: The metabolic syndrome as an example
spellingShingle Cytoprotection by melatonin: The metabolic syndrome as an example
Cardinali, Daniel Pedro
MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
title_short Cytoprotection by melatonin: The metabolic syndrome as an example
title_full Cytoprotection by melatonin: The metabolic syndrome as an example
title_fullStr Cytoprotection by melatonin: The metabolic syndrome as an example
title_full_unstemmed Cytoprotection by melatonin: The metabolic syndrome as an example
title_sort Cytoprotection by melatonin: The metabolic syndrome as an example
dc.creator.none.fl_str_mv Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author Cardinali, Daniel Pedro
author_facet Cardinali, Daniel Pedro
Vigo, Daniel Eduardo
author_role author
author2 Vigo, Daniel Eduardo
author2_role author
dc.subject.none.fl_str_mv MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
topic MELATONINA
SINDROME METABOLICO
INFLAMACION
DIABETES
ENVEJECIMIENTO
INSULINA
dc.description.none.fl_txt_mv Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Fil: Vigo, Daniel Eduardo. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas. Instituto de Investigaciones Biomédicas; Argentina
Abstract: As for metabolic syndrome (MS), several risk factors for cardiovascular disease are known, including elevated blood pressure, hyperinsulinemia, glucose intolerance, and dyslipidemia. We hereby discussed the special role that the chronobiotic/cytoprotective properties of melatonin may have in prevention and treatment of MS. Melatonin levels are consistently reduced in MS. The therapeutic potential of melatonin includes improvement of sleep efficiency and antioxidant and anti-inflammatory properties that derive partly from its role as a metabolic regulator and mitochondrial protector. This article analyzes the actions of melatonin that are relevant to the attenuation of inflammatory responses in MS and how melatonin is effective to curtail MS in animal models of hyperadiposity and ischemic and nonischemic heart failure. The clinical data supporting the therapeutical use of melatonin in human MS are also reviewed. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e., in the 40–100 mg/day range). The off-label use of melatonin is finally discussed.
description Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
publishDate 2021
dc.date.none.fl_str_mv 2021
info:eu-repo/date/embargoEnd/2100-01-01
dc.type.none.fl_str_mv info:eu-repo/semantics/bookPart
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_3248
info:ar-repo/semantics/parteDeLibro
format bookPart
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/15402
978-3-030-61721-9 (online)
10.1007/978-3-030-61721-9_22
Cardinali, D.P., Vigo, D.E. Cytoprotection by Melatonin: The Metabolic Syndrome as an Example [en línea]. En: Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021 doi:10.1007/978-3-030-61721-9_22 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/15402
url https://repositorio.uca.edu.ar/handle/123456789/15402
identifier_str_mv 978-3-030-61721-9 (online)
10.1007/978-3-030-61721-9_22
Cardinali, D.P., Vigo, D.E. Cytoprotection by Melatonin: The Metabolic Syndrome as an Example [en línea]. En: Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021 doi:10.1007/978-3-030-61721-9_22 Disponible en: https://repositorio.uca.edu.ar/handle/123456789/15402
dc.language.none.fl_str_mv spa
language spa
dc.rights.none.fl_str_mv info:eu-repo/semantics/embargoedAccess
eu_rights_str_mv embargoedAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Springer
publisher.none.fl_str_mv Springer
dc.source.none.fl_str_mv Gargiulo, P.Á., Mesones Arroyo, H.L. (eds.). Psychiatry and Neuroscience Update. From Epistemology to Clinical Psychiatry – Vol. IV. Springer, Cham, 2021
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638365913448448
score 13.13397

Publicaciones similares